Erschienen in:
01.03.2011 | SSAT/AHPBA Joint Symposium 2010
SSAT/AHPBA Joint Symposium: Today's Approaches to Colorectal Cancer (CRC) Liver Metastases
verfasst von:
W. Scott Helton
Erschienen in:
Journal of Gastrointestinal Surgery
|
Ausgabe 3/2011
Einloggen, um Zugang zu erhalten
Excerpt
Each year in the USA, approximately 150,000 patients are diagnosed with colorectal cancer with an associated 55,000 attributable deaths.
1 Colorectal cancer is the second most common cause of cancer-related death in the USA, with most patients dying of metastatic disease. Up to 40–50% of patients with colorectal cancer will develop metastasis,
2 with about 10–20% presenting with liver metastasis (CRLM) at the time of diagnosis
3,
4 and another 20–25% developing metachronous liver metastasis some time later.
5,
6 Despite this high incidence of developing metastatic disease, the median survival of patients with CRLM has increased substantially over the past 10 years; patients are living with persistent or recurrent metastatic disease longer and with better quality of life than those treated in the 1980s and 1990s.
7,
8 This improvement in outcome is related to improved patient selection, newer and more aggressive surgical techniques,
9,
10 and more effective chemotherapy agents and regimens.
11 Five-year survival following curative intent surgery of CRLM now approaches 45–60%
12‐
15 and is as high as 20% at 10 years in select individuals.
16 …
